

July 31, 2019



## SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference

JERSEY CITY, N.J., July 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August 7, 2019 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the Investors section of the Company's website: [www.scynexis.com](http://www.scynexis.com). A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

### About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by *Candida*, *Aspergillus* and *Pneumocystis* species. For more information, visit [www.scynexis.com](http://www.scynexis.com).

### CONTACT:

#### Investor Relations

Heather Savelle  
Argot Partners  
Tel: 212-600-1902  
[heather@argotpartners.com](mailto:heather@argotpartners.com)

#### Media Relations

George E. MacDougall  
MacDougall  
Tel: 781-235-3093  
[george@macbiocom.com](mailto:george@macbiocom.com)

View original content: <http://www.prnewswire.com/news-releases/scynexis-inc-to-present-at-the-39th-annual-canaccord-genuity-global-growth-conference-300893615.html>

SOURCE SCYNEXIS, Inc.